Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
نویسندگان
چکیده
BACKGROUND Universal anti-hepatitis-B vaccination of infants and adolescents was implemented in Italy in 1991. We undertook a multicentre study in previously vaccinated individuals to assess the duration of immunity and need for booster, over 10 years after vaccination. METHODS In 1212 children and 446 Italian Air Force recruits vaccinated as infants and adolescents, respectively, we measured the concentrations of antibodies to hepatitis-B surface antigen (anti-HBs) and the presence of antibodies to hepatitis-B core antigen (anti-HBc) at enrollment; postimmunisation values were not available. Individuals positive for anti-HBc were tested for hepatitis B surface antigen (HBsAg) and hepatitis B viral DNA. Individuals with anti-HBs concentrations at 10 IU/L or more were regarded as protected; those with antibody less than 10 IU/L were given a booster dose and retested 2 weeks later. Individuals showing postbooster anti-HBs concentrations of less than 10 IU/L were offered two additional vaccine doses and retested 1 month after the third dose. FINDINGS Protective anti-HBs concentrations were retained in 779 (64%, 95% CI 61.6-67) children and 398 (89%, 86.4-92.1) recruits. We recorded antibody amounts of less than 10 IU/L in 433 children (36%, 33-38.4) and 48 (11%, 7.9-13.6) recruits. One child and four recruits were positive for anti-HBc, but negative for HBsAg and hepatitis B viral DNA. Antibody concentrations were higher in recruits than in children (geometric mean titre 234.8 IU/L vs 32.1 IU/L, p=0.0001). 332 (97%) of 342 children and 46 (96%) of 48 recruits who received a booster showed an anamnestic response, whereas ten (3%) children and two (4%) recruits remained negative for anti-HBs or had antibody concentrations of less than 10 IU/L. Prebooster and postbooster antibody titres were strongly correlated with each other in both groups. All individuals given two additional vaccine doses (eight children and two recruits) showed anti-HBs amounts of more than 10 IU/L at 1 month after vaccination. INTERPRETATION Strong immunological memory persists more than 10 years after immunisation of infants and adolescents with a primary course of vaccination. Booster doses of vaccine do not seem necessary to ensure long-term protection.
منابع مشابه
Vaccination against hepatitis b virus: are Italian medical students sufficiently protected after the public vaccination programme?
BACKGROUND The development of a vaccine against hepatitis B virus (HBV) has been a major achievement in terms of prevention of HBV infection. For the present study, we analysed the long-term immunogenicity and effectiveness of HBV vaccination among healthcare students with different working seniorities. METHODS A cross-sectional study of undergraduate and postgraduate students attending the M...
متن کاملبررسی دوام آنتی بادی anti-HBs و خاطره ایمنی واکسن هپاتیت B ، 18 سال پس از واکسیناسیون دوره نوزادی در دانشجویان دانشگاه تهران
Background The duration of infantile hepatitis B vaccination-induced immunity is still unknown. We assessed antibody persistence and immunological memory to hepatitis B 18 years after vaccination during infancy in Iranian young adults at risk of hepatitis B virus infection due to behavioral or occupational exposures. Methods This study was conducted on 395 freshman students of with a history of...
متن کاملThe factors influencing the immune response to hepatitis B vaccine and persistence of the protection.
Hepatitis B virus (HBV) infection and its sequelae which include cirrhosis and hepatocellular carcinoma is a major public health problem throught the world.The WHO strategy for effective control of HBV infection is vaccination with the surface antigen of virus(HBsAg).The results obtained from a large number of studies demonstrated that the vaccine induces a protective antibody resonse (anti-HB...
متن کاملSafety and Immunogenicity of Hepatitis B Vaccine: a Study on Iranian Navy Personnel
Objective: Preventing communicable diseases in the armed forces (AF) of a country is considered as a national interest and has a great importance. There are limited data on the efficacy of vaccination of the navy personnel. This study was designed to evaluate both the safety and the immunogenicity of a recombinant hepatitis B (HB) vaccine made by Pasteur Institute of Iran (IPI-rHB), in this tar...
متن کاملThe long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy
BACKGROUND Universal hepatitis B virus (HBV) vaccination of newborn babies was introduced in Italy in 1991 and was extended to 12-years-old children for the first 12 years of application so as to cover in a dozen years the Italian population aged 0-24 years. The aim of this study was to identify factors associated with long-term immunogenicity against HBV 17 years after primary vaccination in s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Lancet
دوره 366 9494 شماره
صفحات -
تاریخ انتشار 2005